arrow
A

Alex F. Herrera

city of hope national medical center
H指数:46
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase 1/2 study of favezelimab plus pembrolizumab in anti–PD-1–naive relapsed or refractory classical Hodgkin lymphoma

I期/II期研究:favezelimab联合pembrolizumab治疗抗PD-1初治复发或难治性经典型霍奇金淋巴瘤

2026-10-050
OAAI
Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)

EBV状态和组织学对纳武利尤单抗-AVD与博安拉塞-AVD在晚期经典霍奇金淋巴瘤中患者预后的影响(S1826)

2026-07-310
OA
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab

复发/难治性侵袭性B细胞淋巴瘤接受epcoritamab治疗后的预后因素和生存结局

2026-06-090
OAAI
Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers

纳武利尤单抗联合AVD方案作为经典霍奇金淋巴瘤患者的一线治疗方案:一项来自20家美国中心的真实世界分析

2026-03-310
OAAI
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin 联合 R-ICE(PolaR-ICE)作为弥漫性大B细胞淋巴瘤的二线治疗方案

2026-03-170
PRE
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

利萨库肽马瑞卢赛尔在复发或难治性大B细胞淋巴瘤患者中的真实世界结局

Blood
IF23.1
2026-03-050
OA
Hodgkin Lymphoma, Version 1.2026

霍奇金淋巴瘤,版本1.2026

2026-02-011
PRE
Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial

Shouse, G.; Chen, C.; Muir, A.; Popplewell, L.; Siddiqi, T.; Zain, J.; Herrera, A.F.; Danilova, O.; Roleder, C.; Wang, L.; et al. 在Richter’s transformation或transformed non-Hodgkin lymphoma患者中copanlisib与nivolumab联合治疗的安全性与有效性:一项I期临床试验结果。Haematologica 2025. [Google Scholar] [CrossRef]

2026-01-013
OA
ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma

ASTCT关于经典霍奇金淋巴瘤移植治疗的临床实践建议

2025-12-300
OAAI
Association of clonal haematopoiesis and diabetes with outcomes after autologous haematopoietic cell transplantation
2025-12-010
OAAI
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study

Mosunetuzumab对复发/难治性滤泡性淋巴瘤的老年患者具有疗效且耐受性良好:一项I/II期研究的亚组分析

2025-11-010
OAAI
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration

Polatuzumab vedotin在CNS淋巴瘤中的应用:关于血脑屏障穿透的可行性研究

2025-10-100
OAAI
Camidanlumab Tesirine in Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study

Camidanlumab Tesirine 在复发或难治性经典型霍奇金淋巴瘤中的应用:一项 II 期研究

2025-08-190
OAAI
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

CD19 CAR T细胞疗法治疗原发性纵隔大B细胞淋巴瘤:一项CIBMTR分析

2025-08-110
PRE
CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis

CD19靶向CAR T疗法治疗转化型滤泡性淋巴瘤:一项CIBMTR分析

2025-08-050
PRE